Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:4/14/2009

called CEL-2000, has shown excellent data against rheumatoid arthritis in animal tests.

Sincerely,

Geert Kersten

Chief Executive Officer

When used in this report, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10- K/A for the year ended September 30, 2008. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
2. CEL-SCI Corporation Releases Letter to Shareholders
3. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
4. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
5. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
6. CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
8. CEL-SCI Corporation Announces 2007 Financial Results
9. CEL-SCI Corporation Reports First Quarter Financial Results
10. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
11. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Chindex International, Inc. ("Chindex" or ... the completion of its acquisition by Healthy Harmony Holdings, ... Healthy Harmony is an affiliate of TPG, Shanghai Fosun ... Lipson , the CEO of the Company. ... stockholders at a special meeting of stockholders held on ...
(Date:9/29/2014)... and PARIS , Sept. ... and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced ... investigational therapy that blocks IL-4 and IL-13 signaling, met ... chronic sinusitis with nasal polyps (CSwNP) who did not ... suggest the potential of dupilumab for use in the ...
(Date:9/29/2014)... 29, 2014 Pharmacists have an important ... according to good clinical trials practices. The Hematology/Oncology ... Service Best Practice Standards, the first of its ... guidance for pharmacists and institutions that conduct clinical ... Standards emphasizes the critical role of the pharmacist ...
Breaking Medicine Technology:Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 2Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 3Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 4Chindex Completes Go-Private Transaction With Healthy Harmony Holdings, L.P. 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 2Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 3Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 4Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 5Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 6Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps 7HOPA Introduces First Investigational Drug Service Best Practice Standards For Institutions And Infusion Clinics 2HOPA Introduces First Investigational Drug Service Best Practice Standards For Institutions And Infusion Clinics 3
...  BARRX Medical Inc., a leader in developing minimally invasive ... precancerous tissue from the gastrointestinal tract, announces today that ... by Covidien.  Covidien is a leading global provider of ... devices.  Covidien will acquire all of ...
... 2011 Medizone International (MZEI:OB MZEI:QB), a leading-edge ... and sterilization systems and SMTC Corporation (Nasdaq: SMTX, ... (EMS) provider, today jointly announce a new partnership ... . Medizone International CEO Edwin Marshall ...
Cached Medicine Technology:BARRX Medical, Inc. Announces Definitive Agreement to be Acquired by Covidien 2BARRX Medical, Inc. Announces Definitive Agreement to be Acquired by Covidien 3AsepticSure™ Production Agreement Awarded to SMTC 2AsepticSure™ Production Agreement Awarded to SMTC 3AsepticSure™ Production Agreement Awarded to SMTC 4
(Date:9/30/2014)... Visit Pam and Steve’s quiet home in the ... a loving couple facing the most monumental challenge of ... Steve was diagnosed with ALS – more commonly known ... the couple’s second wedding anniversary. Pam is now ... “Care, Support & ALS,” that’s part of the ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 A highlight ... Optics (AMO) at the American Academy of Ophthalmology meeting ... LASIK surgeon Jeffrey Martin, MD on the ... is the Managing Partner of North Shore Eye Care ... SUNY Stony Brook. , This year’s 118th Annual American ...
(Date:9/30/2014)... News) -- Herceptin is the best drug treatment for ... remain the standard of care for that type of ... trial. HER2-positive breast cancers tend to be more ... the Mayo Clinic. For the study, more than ... or Tykerb (lapatinib) in addition to standard chemotherapy. ...
(Date:9/30/2014)... September 30, 2014 The St. Louis ... SLUCare Physician Group, comprised of more than 500 physicians, ... number of initiatives. With the recent addition of ... strengthening its market footprint to better respond to the ... , SLPA is a physician-led clinically integrated network (CIN) ...
(Date:9/30/2014)... Francisco, California (PRWEB) September 30, 2014 ... expected to reach USD 8,020.1 million by 2020, ... Research, Inc. Growing demand for personalized medicine and ... diagnostic technologies are expected to be key factors ... Moreover, the growing global base of geriatric population ...
Breaking Medicine News(10 mins):Health News:Hospice Provides Care and Support to Patients and Family Caregivers with ALS 2Health News:Global Laser Technology Leader Selects Jeffrey Martin, MD To Address Colleagues During International Symposium In Chicago 2014 2Health News:Global Laser Technology Leader Selects Jeffrey Martin, MD To Address Colleagues During International Symposium In Chicago 2014 3Health News:St. Louis Physician Alliance Expands Network and Market Footprint with Recent Addition of SLUCare Physician Group 2Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 2Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 3Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 4Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 5Health News:Global Molecular Diagnostics Market Is Expected To Be Worth $8,020.1 million by 2020: Grand View Research, Inc. 6
... has invited best-selling author and noted physician Abraham Verghese to ... and Human Values at 7:30 p.m., Monday, Oct. 24 at ... Indian-American immigrant to the United States, Dr. Verghese,s varied professional ... India studies program at UH," said Lois Zamora, chair of ...
... Phase III trial of RTS,S*, published online today in the ... malaria vaccine candidate to provide young African children with significant ... and tolerability profile. The results were announced today at the ... in Seattle, Washington. Half the world,s population is at ...
... HealthDay Reporter , MONDAY, Oct. 17 (HealthDay ... conventional Pap tests as a cervical cancer screening tool ... The U.S. Preventive Services Task Force ... researchers are now seeking to fine-tune these guidelines. The ...
... (IAN Project) launches a national survey to study the ... (ASD). Bullying, a pervasive problem among youth, has attracted ... lasting, and sometimes tragic, effects on children and teenagers ... be especially vulnerable targets due to their social deficits ...
... (HealthDay News) -- Experts at the American Academy of Pediatrics ... for sudden infant death syndrome (SIDS). Those are two ... SIDS guidelines. Since 1992, when the AAP recommended that ... SIDS has declined sharply in the United States, according to ...
... Cypress, CA, October 18, 2011 Technology has radically ... this more evident than in the field of gynecologic ... teaching minimally invasive treatment for women,s health problems, will ... tools among the hundreds of postgraduate courses and practice ...
Cached Medicine News:Health News:Dr. Abraham Verghese to give John P. McGovern Lecture on Oct. 24 2Health News:Malaria vaccine candidate, RTS,S reduces the risk of malaria by half in African children 2Health News:Malaria vaccine candidate, RTS,S reduces the risk of malaria by half in African children 3Health News:Pap Test Still Best for Cervical Cancer Screening, Experts Say 2Health News:Pap Test Still Best for Cervical Cancer Screening, Experts Say 3Health News:National survey will measure how bullying impacts children with autism 2Health News:Breast-Feeding, Vaccinations Lower SIDS Risk, Experts Say 2Health News:Innovations in minimally invasive surgery and education are highlights of 40th AAGL Global Congress 2Health News:Innovations in minimally invasive surgery and education are highlights of 40th AAGL Global Congress 3Health News:Innovations in minimally invasive surgery and education are highlights of 40th AAGL Global Congress 4
... 5 pages of various contrast levels showing 5 ... 9.5M. Contrast levels are 25%, 10%, 5%, 2.5% ... at several different distances. These two sets are ... different set of symbols to guard against ...
Directional `E' and `C' test....
9" X 14" translucent plastic may be used with illuminated test cabinet or as a wall chart 20/200 to 20/15....
... recording unit suitable for a wide range ... up to 16 input channels. Examples include ... unit is capable of recording at speeds ... second continuously to disk, and is compatible ...
Medicine Products: